Skip to content

Opko Health OPK Total costs & expenses

Total costs & expenses at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$34.35M-57.9%
Exelixis logo
ExelixisEXEL
$359.47M-2.5%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$363.52M+30.5%
Quest Diagnostics logo
Quest DiagnosticsDGX
Abbott logo
AbbottABT
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's total costs & expenses?
Opko Health (OPK) reported total costs & expenses of $175.21M in Q1 2026.
How has Opko Health's total costs & expenses changed year-over-year?
Opko Health's total costs & expenses decreased by 19.3% year-over-year, from $217.12M to $175.21M.
What is the long-term trend for Opko Health's total costs & expenses?
Over 3 years (2022 to 2025), Opko Health's total costs & expenses has grown at a -16.2% compound annual growth rate (CAGR), from $1.23B to $724.29M.
What does total costs & expenses mean?
This metric aggregates all operating and non-operating costs incurred by the company to generate revenue, including cost of goods sold, research and development, and selling, general, and administrative expenses. It serves as a comprehensive measure of the company's total expenditure burden during a reporting period. Monitoring this helps evaluate the company's cost structure and operational efficiency relative to its revenue generation.